Long-term follow-up and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution

Oncology
J AparicioC Herranz

Abstract

The records of 116 patients from a single center (1970-1993) with newly diagnosed Ewing's sarcoma or primitive neuroectodermal tumor were reviewed retrospectively. The aim of this study was to ascertain the impact of pretreatment variables on disease-free survival. Median age was 14 years (range 1-34). Twenty patients presented with metastatic disease. Treatment consisted of systemic multiagent chemotherapy plus local irradiation (39%), wide resection (22%), or both (35%). Median potential follow-up was 10.7 years (range 2-26). Three patients developed second malignancies (1 breast carcinoma, 2 acute myeloid leukemias). Median time to relapse was 24 months (range 3-143). The actuarial disease-free survival was 37.4% at 5 years, 33.3% at 10 years and 27.8% at 15 years. Neoadjuvant chemotherapy and a therapy-induced tumor necrosis > or = 90% were associated with a better outcome. Patients undergoing surgical resection had a superior disease-free survival than those treated without surgery (45 vs. 18% at 10 years, p = 0.0009). Multiple regression analysis showed that raised serum lactate dehydrogenase levels (p < 0.001), hypoalbuminemia (p = 0.001) and distant metastases at diagnosis (p = 0.03) were independent adverse prognostic ...Continue Reading

Citations

May 10, 2005·Expert Review of Anticancer Therapy·Mihir M ThackerSean P Scully
Mar 15, 2006·Cancer·Bridget F KoontzEdward C Halperin
May 25, 2006·The Oncologist·Mark BernsteinHerbert Juergens
Jun 7, 2007·Journal of Pediatric Hematology/oncology·Stefano FerrariPiero Picci
Jan 21, 2017·Molecular and Clinical Oncology·Suoyuan LiYingqi Hua
Jun 24, 1999·Annals of Surgical Oncology·S AgrawalD G Coit
Apr 2, 2004·Clinical Orthopaedics and Related Research·Roberto CasadeiMario Mercuri
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G BacciP Picci
May 17, 2012·Clinical Sarcoma Research·Annmeik M van MaldegemAndrew B Hassan
May 2, 2015·Journal of Pediatric Hematology/oncology·Robert Diaz-BeveridgeJorge Aparicio
Mar 15, 2005·American Journal of Clinical Pathology·Cheryl M CoffinHolly Zhou
Dec 19, 2008·The Journal of Hand Surgery, European Volume·O A AnakwenzeP C Amadio
Dec 12, 2003·Cancer·Bruno FuchsMichael G Rock
Feb 25, 2021·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Alberto RighiAngelo Paolo Dei Tos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.